Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics' stock price has been impacted by several events. In November 2025, shares plunged due to a clinical hold on NTLA-2001 following safety concerns. Promising results for NTLA-2002 initially led to negative investor reaction in July 2025. In January 2026, the stock surged due to ARK Investment Management increasing its stake. Analyst ratings are mixed, with a consensus "Hold" rating. Insider selling by executives was reported in early January 2026.

As a clinical-stage biotechnology company, Intellia Therapeutics does not have traditional demand seasonality. Its revenue is primarily generated through partnership agreements and milestone payments. Seasonal patterns in stock performance relate to investor behavior rather than demand for therapeutic products.

Intellia Therapeutics is a clinical-stage biotechnology company focused on developing CRISPR-based gene editing therapeutics. They have both in vivo programs, where CRISPR is administered intravenously, and ex vivo programs, which utilize engineered human cells. Key product candidates include NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. The company has collaborations with companies like Regeneron and Novartis.

Intellia Therapeutics is headquartered in Cambridge, Massachusetts, United States, where its primary operational and research activities are concentrated.

Intellia Therapeutics' brand reputation has been affected by the clinical hold on NTLA-2001 due to safety concerns, leading to negative investor sentiment. The company faces financial challenges, including negative margins and declining earnings growth. However, it is recognized as a leader in gene-editing technology and has strategic collaborations, which positively contributes to its scientific standing.

Intellia Therapeutics has significant institutional ownership, ranging from approximately 89.93% to 90.34%. Major institutional owners include Ark Investment Management LLC, Vanguard Group Inc, and Blackrock Inc. Individual ownership includes insiders holding approximately 1.81% to 3.01% of the company's stock. Rachel E. Haurwitz is the largest individual shareholder, owning 5.59 million shares.